LRRK2 Phosphorylation Detection via Proximity Ligation Assay
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biochemical understanding of molecular mechanisms leading to neuronal loss in Parkinson's disease, particularly in relation to LRRK2 mutations, hindering the development of causative treatment strategies.
Innovation Solution
The development of methods and compositions for detecting LRRK2 phosphorylation, including phospho-specific antibodies and proximity ligation assays, to elucidate signaling pathways and kinase activity, which can be used for diagnostic and therapeutic applications in Parkinson's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If conventional methods are used to study Parkinson's disease mechanisms, then general disease knowledge can be obtained, but specific biochemical understanding of LRRK2-mediated molecular mechanisms is lacking
Solution Approach 1:
The patent segments the detection process into multiple specialized components: phospho-specific antibodies for detecting phosphorylated LRRK2, total LRRK2 antibodies for detecting overall LRRK2 levels, and proximity ligation assays for detecting protein-protein interactions. This segmentation allows each component to be optimized for its specific function, providing comprehensive biochemical understanding while maintaining manageable assay complexity through modular design.
Solution Approach 2:
The patent employs proximity ligation assays as an intermediary technique that bridges the gap between detecting individual phosphorylated residues and understanding overall LRRK2 signaling pathways. The PLA uses paired antibodies and DNA-mediated signal amplification to detect protein-protein interactions and phosphorylation events simultaneously, providing intermediate-level biochemical insight that connects molecular details to pathway-level understanding.
2Measurement precision
If phospho-specific antibodies and proximity ligation assays are developed to detect LRRK2 phosphorylation, then molecular mechanisms can be elucidated, but the complexity of diagnostic and therapeutic applications increases
Solution Approach 1:
The patent performs preliminary actions by developing and validating phospho-specific antibodies against predetermined phosphorylation sites on LRRK2 before applying them to clinical samples. The antibodies are raised against phosphopeptides containing specific phosphorylation motifs, and their specificity is established through controlled experiments with phospho-deficient mutants. This preliminary characterization ensures high measurement precision while reducing downstream assay complexity by eliminating the need for de novo antibody validation in each application.
Solution Approach 2:
The patent exploits parameter changes in the phosphorylation state of LRRK2 as a readout of kinase activity and signaling pathway activation. By monitoring changes in phosphorylation levels at specific residues (e.g., Ser910, Ser935, Ser955, Ser973) in response to genetic mutations, pharmacological inhibitors, or disease progression, the assay translates complex molecular mechanisms into quantifiable parameter changes that maintain measurement precision while simplifying data interpretation.
Data Source
AI summary
Disclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinson's Disease, antibodies that specifically bind to the novel phosphorylation sites, and laboratory and clinical uses thereof.